Abstract
OBJECTIVE: To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA).
METHODS: Data from patients with PsA who received ETN alone (n = 322) or combined with methotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies.
RESULTS: Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80% and 83%) and the American College of Rheumatology improvements of 20% (ACR20; both 70%); numerically higher proportions receiving monotherapy achieved ACR50 (55% vs 48%) and ACR70 (35% vs 27%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire-Disability Index improvement.
CONCLUSION: ETN with and without MTX provided similar benefits in active PsA.
| Original language | English |
|---|---|
| Pages (from-to) | 1063-1067 |
| Journal | The Journal of Rheumatology |
| Volume | 43 |
| Issue number | 6 |
| Early online date | 1 May 2016 |
| DOIs | |
| Publication status | Published - Jun 2016 |